# Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

> **NCT05995899** · PHASE4 · COMPLETED · sponsor: **Kyle Staller, MD, MPH** · enrollment: 36 (actual)

## Conditions studied

- IBS
- IBS - Irritable Bowel Syndrome

## Interventions

- **DRUG:** Tenapanor

## Key facts

- **NCT ID:** NCT05995899
- **Lead sponsor:** Kyle Staller, MD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-06
- **Primary completion:** 2025-12-17
- **Final completion:** 2025-12-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05995899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05995899, "Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05995899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*